Incyte Corporation (INCY) Director Paul A. Friedman Sells 28,507 Shares of Stock

Incyte Corporation (NASDAQ:INCY) Director Paul A. Friedman sold 28,507 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $105.24, for a total transaction of $3,000,076.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Incyte Corporation (NASDAQ INCY) opened at $98.95 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. Incyte Corporation has a 12-month low of $98.49 and a 12-month high of $153.15.

Incyte Corporation (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.11. The company had revenue of $381.50 million during the quarter, compared to analysts’ expectations of $360.34 million. Incyte Corporation had a negative net margin of 10.90% and a negative return on equity of 12.91%. The firm’s revenue for the quarter was up 41.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.19 earnings per share. research analysts expect that Incyte Corporation will post -1.33 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.truebluetribune.com/2017/11/21/incyte-corporation-incy-director-paul-a-friedman-sells-28507-shares-of-stock.html.

INCY has been the subject of several recent analyst reports. Oppenheimer Holdings, Inc. reiterated a “hold” rating and set a $135.00 price objective on shares of Incyte Corporation in a research note on Thursday, August 31st. BMO Capital Markets reduced their price objective on shares of Incyte Corporation from $163.00 to $162.00 and set an “outperform” rating for the company in a research note on Thursday, October 26th. Barclays PLC reiterated an “overweight” rating and set a $165.00 price objective (down previously from $180.00) on shares of Incyte Corporation in a research note on Wednesday, August 2nd. Royal Bank Of Canada initiated coverage on shares of Incyte Corporation in a research note on Thursday, September 14th. They set a “sector perform” rating and a $136.00 price objective for the company. Finally, Raymond James Financial, Inc. upgraded shares of Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 price objective for the company in a research note on Monday, September 11th. Seven research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $146.41.

Hedge funds and other institutional investors have recently modified their holdings of the company. Oppenheimer Asset Management Inc. raised its position in shares of Incyte Corporation by 9.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 27,147 shares of the biopharmaceutical company’s stock valued at $3,418,000 after buying an additional 2,455 shares during the last quarter. Pinebridge Investments L.P. raised its position in shares of Incyte Corporation by 122.0% in the second quarter. Pinebridge Investments L.P. now owns 74,590 shares of the biopharmaceutical company’s stock valued at $9,392,000 after buying an additional 40,992 shares during the last quarter. Calamos Advisors LLC raised its position in shares of Incyte Corporation by 37.7% in the second quarter. Calamos Advisors LLC now owns 113,132 shares of the biopharmaceutical company’s stock valued at $14,244,000 after buying an additional 30,990 shares during the last quarter. Inverness Counsel LLC NY acquired a new stake in shares of Incyte Corporation in the third quarter valued at about $330,000. Finally, Tredje AP fonden raised its position in shares of Incyte Corporation by 63.4% in the second quarter. Tredje AP fonden now owns 22,446 shares of the biopharmaceutical company’s stock valued at $2,826,000 after buying an additional 8,706 shares during the last quarter. Institutional investors and hedge funds own 89.60% of the company’s stock.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply